fig1

Figure 1. Therapeutic targets of biologics currently undergoing clinical trials for systemic lupus erythematosus. Therapeutic targets include molecules expressed on immune cells and cytokines produced by immune cells. BAFF: B-cell activating factor; CD40L: CD40 ligand; TACI: transmembrane activator and calcium-modulating cyclophilin ligand interactor; ICOS: inducible T-cell costimulator. ICOSL: ICOS ligand; IFNAR: type I interferon receptor. BDCA2: blood dendritic cell antigen 2; ILT7: immunoglobulin-like transcript 7; MHC II: major histocompatibility complex class II. Created in BioRender. Kanda, K. (2026) https://BioRender.com/q97c492.